About Clarity

Clarity is a clinical-stage radiopharmaceutical company developing next-generation products to address the growing need for radiopharmaceuticals in oncology.

Clarity is a global leader in next-generation radiopharmaceuticals with its Targeted Copper Theranostic (TCT) platform of products. Clarity’s products use the “perfect pairing” of copper isotopes, copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy, which deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current-generation theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market.

Product Development

Clarity’s three core clinical-stage theranostic products, SAR-bisPSMA, SARTATE, and SAR-Bombesin, each contain a different targeting agent that binds to specific receptors that are present on different cancer cells.

These three products are in clinical development for the diagnosis and/or treatment of various cancers addressing unmet clinical needs. 

The versatility of the SAR Technology platform enables Clarity to pursue a Discovery Program focused on developing new products and new intellectual property (IP) for a range of cancers. Clarity has a robust IP position with a broad patent portfolio covering its platform, pipeline and products. 

The Perfect Pairing 

The term “perfect pairing” relates to the unique characteristics of the two copper isotopes, copper-64 for diagnosis and copper-67 for therapy. In addition to clinical benefits, this pairing also provides supply and logistical advantages over the current generation of theranostics. TCTs represent a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market.